Guggenheim Maintains Buy on Sagimet Biosciences, Raises Price Target to $26

Sagimet Biosciences Announces Closing of Underwritten Offering of Series A Common Stock and Pre-Funded Warrants

Oppenheimer Maintains Outperform on Sagimet Biosciences, Raises Price Target to $38

Citizens Maintains Market Outperform on Sagimet Biosciences, Lowers Price Target to $27

Sagimet Biosciences Inc. (SGMT) Discusses 52-Week Phase 3 Data and U.S. Phase 3 Plans for Denifanstat in Moderate to Severe Acne Transcript

Sector Update: Healthcare Stocks Softer Wednesday Afternoon

Sagimet Biosciences Surges Forward With Successful Acne Clinical Data and Capital Raise

Sagimet Biosciences Shares Rise 12% After Denifanstat Phase 3 Acne Trial Data

Sagimet Raises $115M At Premium To Fund Phase 3 Acne Drug Trial – SGMT Stock Surges Pre-Market

Sagimet Prices $115 Million Offering of Series A Shares, Warrants; Shares Rise Pre-Bell

Sagimet Biosciences Announces Pricing of $115.0 Million Underwritten Offering of Series A Common Stock and Pre-Funded Warrants

Sagimet Announces Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne Presented at EADV 2026

Sagimet Biosciences (SGMT) Attracts Attention After Russel Indexes Inclusion